Bengaluru: The Karnataka High Court has dismissed a petition filed by Life Vision Healthcare and its managing partner seeking to quash criminal proceedings over a batch of Impcal Tablets reported to be not of standard quality.
Rejecting objections concerning a two-day delay in forwarding the sample for analysis, the loss of an opportunity for re-testing and the managing partner’s alleged lack of responsibility, the court held that the allegations warranted a full-fledged trial.
It clarified that it was expressing no opinion on the merits and permitted the petitioners to raise all their contentions before the trial court.

Justice Rajesh Rai K passed the order on November 2, 2026, in Life Vision Healthcare v. State of Karnataka, Criminal Petition No. 1600 of 2024, bearing neutral citation 2026:KHC:60798. The petition challenged proceedings in C.C. No. 43/2023, pending before the Special Court for Economic Offences, Bengaluru, for alleged contravention of Section 18(a)(i), punishable under Section 27(d), of the Drugs and Cosmetics Act, 1940.

The case concerns Impcal Tablets—Calcium Orotate with Vitamin D3 Tablets I.P.—bearing batch number LTA-2497, manufactured in September 2019 and carrying an expiry date of February 2021. According to the prosecution, the batch manufactured and marketed by Life Vision Healthcare was reported to be not of standard quality in respect of the “Assay for Vitamin D3” parameter.

The proceedings originated in a private complaint filed by the Assistant Drugs Controller, Bengaluru Circle-1, under Section 200 of the Code of Criminal Procedure against the manufacturer, its managing partner and two other accused. Life Vision Healthcare and its managing partner, accused Nos. 1 and 2, subsequently approached the High Court under Section 482 of the Cr.P.C., seeking to quash the proceedings against them.

The record examined by the High Court showed that a legal sample of the disputed batch was drawn from a pharmaceutical establishment on February 18, 2020, with Form No. 17 issued on the same date. On February 20, 2020, the sample was forwarded for chemical analysis with the memorandum in Form No. 18.

The concerned Assistant Drugs Controller received the test report on August 24, 2020. The report declared the sample not of standard quality concerning its Vitamin D3 assay. On August 25, 2020, the officer issued a notice to the pharmaceutical establishment under Sections 18A and 18B of the Act, accompanied by the report in Form No. 13. In response, the establishment disclosed that it had purchased the drug from the petitioners.

The High Court also recorded that the petitioners were informed of the adverse test result through a communication dated August 28, 2020, enclosing a copy of the report. They subsequently requested re-analysis through a letter dated April 15, 2021, by which time the batch’s stated shelf life had expired.

After examining the private complaint, Forms Nos. 13, 17 and 18, the statutory notices, correspondence, replies and supporting documents, the trial court took cognizance and issued summons. The petitioners challenged that action, principally alleging failure to apply judicial mind and non-compliance with statutory safeguards.

Counsel for the petitioners argued that Section 23(4)(i) required the seized sample to be forwarded to the Government Analyst “forthwith”. According to them, forwarding it two days after collection breached that mandatory requirement and undermined the prosecution.

They further contended that the complaint had been instituted only after the drug’s shelf life expired, depriving them of their valuable statutory right under Sections 25(3) and 25(4) to seek re-analysis by the Central Drugs Laboratory. They maintained that this loss prejudiced their defence and made continuation of the proceedings legally unsustainable.

A separate objection concerned the prosecution of the managing partner. The petitioners argued that he could not be prosecuted merely because he held that position. They submitted that there were no specific allegations or material establishing his involvement in, or responsibility for, the manufacturer’s day-to-day business.

Supporting these arguments, the petitioners relied on Medicamen Biotech Ltd. v. Rubina Bose, Drug Inspector, (2008) 7 SCC 196; State of Punjab v. National Organic Chemical Industries Ltd., (1996) 11 SCC 613; Inox Air Products Ltd. v. State of Andhra Pradesh, 2025 SCC OnLine SC 209; and Lalankumar Singh v. State of Maharashtra, 2022 SCC OnLine SC 1383.

Opposing the petition, the State, represented by High Court Government Pleader Mahesha P, argued that the complaint prima facie disclosed the managing partner’s active involvement in the manufacturer’s affairs and functioning. On that basis, the State submitted that he was liable to face prosecution alongside the manufacturer.

The State also disputed the claim of procedural irregularity. It explained that the sample had first been collected from the pharmaceutical establishment, tested and found not of standard quality. Further enquiries then disclosed the petitioners as its supplier, following which the authorities proceeded against the accused in accordance with the prescribed procedure.

The Government Pleader submitted that special circumstances and justifiable reasons could permit an extension of the period for conducting analysis. In the present case, the State maintained that there was neither procedural irregularity nor undue delay in forwarding the sample. It also relied on the Government Analyst’s report as material establishing a prima facie case and argued that the prosecution should not be interrupted at the threshold.

Examining the re-analysis objection, the High Court placed particular emphasis on the chronology. Although the petitioners requested re-testing on April 15, 2021, they had already been informed of the adverse result through the August 28, 2020 communication.

The court observed that the petitioners did not seek re-analysis within a reasonable time after receiving that intimation and approached the authority only after nearly eight months. It therefore regarded the request as belated.

Since the tablets expired in February 2021, the shelf life had already ended when the request was made. On the material before it, the court held that the resulting inability to undertake further analysis could not, by itself, be attributed to procedural failure or negligence by the respondent or the concerned officer. It accordingly declined to accept the petitioners’ objection on that ground.

Addressing the two-day interval between collection and dispatch, the court held that there was no inordinate delay. It explained that the statutory expression “forthwith” could not be read as requiring immediate dispatch without completing the other procedures contemplated by the Act, including the necessary sampling steps and notice to the retailer.

The court stated:

“Therefore, forwarding the seized drug sample for chemical analysis within two days cannot, in the facts and circumstances of the present case, be construed as an undue or unexplained delay.”

The court also rejected the managing partner’s request for relief at this stage. It noted that the petitioners had not placed cogent or reliable material before it to substantiate the assertion that he was unconnected with the day-to-day affairs of the business. Conversely, the complaint contained allegations prima facie indicating his active involvement in its affairs and daily functioning.

In view of those specific allegations, the court held that the judgments cited by the petitioners were distinguishable on their facts and did not apply to the case before it. Its reasoning was thus based on the complaint and available material, rather than the managing partner’s designation alone.

Considering the allegations as a whole, Justice Rajesh Rai K observed that the case concerned the manufacture and sale of drugs found to be not of standard quality. The court emphasised that, if established, such allegations had consequences for public health and required examination at trial.

It observed:

“The allegations, if established, have a direct bearing on public health and cannot be lightly brushed aside at this stage. The matter, therefore, warrants a full-fledged trial, wherein the respective parties will have an opportunity to establish their case in accordance with law.”

The court expressly preserved the petitioners’ opportunity to contest the prosecution before the trial court, stating:

“Needless to observe that the petitioners are at liberty to urge all the contentions raised herein before the learned Magistrate during the course of trial.”

Dismissing the quashing petition, the High Court delivered the following exact operative ruling in paragraph 23:

“In view of the foregoing discussion, and without expressing any opinion on the merits of the case, I am of the considered opinion that the petition does not merit consideration. Accordingly, the petition stands dismissed.”

To view the order, click the link below:

Tags:    

Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.

NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .